Skip to content

Study · Animal study (in vivo) · 2025

6 results

An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant.

Hu D, Zhang X, Gong S, Ma W, Cheng B, Yang J, Yan L, Li B, Qiu T, Wang X

Colloids and surfaces. B, Biointerfaces25 Jul 2025Cited by 7 (Europe PMC)

PMID40716276 (opens in a new tab)DOI10.1016/j.colsurfb.2025.114982 (opens in a new tab)PepBankPUB-40716276
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In an LPS-induced inflammation model in vivo and in vitro, GHK‑Cu@CMHA gel reduced levels of inflammatory factors.

    In plain wordsIn animal and cell tests of induced inflammation, the GHK‑Cu filler gel lowered inflammatory markers.

    Peptide
    GHK-Cu
    Outcome
    DecreaseInflammatory factor levels
    Study

    n: not reported in source

    LPS-induced inflammation model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the model of LPS-induced inflammation model in vivo and in vitro, GHK-Cu@CMHA gel reduced levels of inflammatory factors and Reactive oxygen species (ROS) levels decreased, while superoxide dismutase (SOD) activity was enhanced.
    1 context sentence
    Summary · context
    This study developed an injectable filler with enhanced anti-inflammatory and antioxidant effects by adsorbing glycyl-L-histidyl-L-lysine copper complex (GHK-Cu) onto hydroxyapatite microspheres (HAPs), marking the first combination of HAPs and GHK-Cu to address inflammation caused by soft tissue fillers.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In an LPS-induced inflammation model in vivo and in vitro, GHK‑Cu@CMHA gel decreased reactive oxygen species levels.

    In plain wordsIn animal and cell tests of induced inflammation, the GHK‑Cu filler gel lowered reactive oxygen species.

    Peptide
    GHK-Cu
    Outcome
    DecreaseReactive oxygen species levels
    Study

    n: not reported in source

    LPS-induced inflammation model
    Outcome group
    Oxidative stress · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the model of LPS-induced inflammation model in vivo and in vitro, GHK-Cu@CMHA gel reduced levels of inflammatory factors and Reactive oxygen species (ROS) levels decreased, while superoxide dismutase (SOD) activity was enhanced.
    1 context sentence
    Summary · context
    This study developed an injectable filler with enhanced anti-inflammatory and antioxidant effects by adsorbing glycyl-L-histidyl-L-lysine copper complex (GHK-Cu) onto hydroxyapatite microspheres (HAPs), marking the first combination of HAPs and GHK-Cu to address inflammation caused by soft tissue fillers.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In an LPS-induced inflammation model in vivo and in vitro, GHK‑Cu@CMHA gel enhanced superoxide dismutase activity.

    In plain wordsIn animal and cell tests of induced inflammation, the GHK‑Cu filler gel raised the activity of an antioxidant enzyme.

    Peptide
    GHK-Cu
    Outcome
    IncreaseSuperoxide dismutase activity
    Study

    n: not reported in source

    LPS-induced inflammation model
    Outcome group
    Oxidative stress · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the model of LPS-induced inflammation model in vivo and in vitro, GHK-Cu@CMHA gel reduced levels of inflammatory factors and Reactive oxygen species (ROS) levels decreased, while superoxide dismutase (SOD) activity was enhanced.
    1 context sentence
    Summary · context
    This study developed an injectable filler with enhanced anti-inflammatory and antioxidant effects by adsorbing glycyl-L-histidyl-L-lysine copper complex (GHK-Cu) onto hydroxyapatite microspheres (HAPs), marking the first combination of HAPs and GHK-Cu to address inflammation caused by soft tissue fillers.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In the LPS-induced inflammation model, H&E and Masson staining revealed significant collagen deposition with GHK‑Cu@CMHA gel.

    In plain wordsIn the animal and cell tests, tissue staining showed more collagen build-up with the GHK‑Cu filler gel.

    Peptide
    GHK-Cu
    Outcome
    IncreaseCollagen deposition
    Study

    n: not reported in source

    LPS-induced inflammation model
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this process, H&E staining and Masson staining revealed significant collagen deposition.
    1 context sentence
    Summary · context
    This study developed an injectable filler with enhanced anti-inflammatory and antioxidant effects by adsorbing glycyl-L-histidyl-L-lysine copper complex (GHK-Cu) onto hydroxyapatite microspheres (HAPs), marking the first combination of HAPs and GHK-Cu to address inflammation caused by soft tissue fillers.

Studies that did not test the peptide alone2

In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHK-Cu.

  1. 05LabNot a test of GHK-Cu aloneIn vitro (cell-free)Other

    GHK‑Cu@CMHA gel showed sustained release of GHK‑Cu for 7 days.

    In plain wordsIn lab tests, the GHK‑Cu filler gel released GHK‑Cu slowly for 7 days.

    Peptide
    GHK-Cu
    Outcome
    Not applicableSustained release duration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Sustained release duration
    7 days
    GHK-Cu@CMHA

    Source sentences

    Summary
    GHK-Cu@CMHA exhibits sustained release properties for 7 days, which ensures prolonged therapeutic effects, minimizes peptide waste and reduces injection frequency, with good flowability and injectability.
    1 context sentence
    Summary · context
    This study developed an injectable filler with enhanced anti-inflammatory and antioxidant effects by adsorbing glycyl-L-histidyl-L-lysine copper complex (GHK-Cu) onto hydroxyapatite microspheres (HAPs), marking the first combination of HAPs and GHK-Cu to address inflammation caused by soft tissue fillers.

    In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHK-Cu.

  2. 06LabNot a test of GHK-Cu aloneIn vitro (cell-free)Other

    GHK‑Cu@CMHA gel had good flowability and injectability.

    In plain wordsIn lab tests, the GHK‑Cu filler gel flowed well and could be injected.

    Peptide
    GHK-Cu
    Outcome
    Not applicableFlowability and injectability
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    with good flowability and injectability.
    1 context sentence
    Summary · context
    This study developed an injectable filler with enhanced anti-inflammatory and antioxidant effects by adsorbing glycyl-L-histidyl-L-lysine copper complex (GHK-Cu) onto hydroxyapatite microspheres (HAPs), marking the first combination of HAPs and GHK-Cu to address inflammation caused by soft tissue fillers.

    In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHK-Cu.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.